Adyn is a precision medicine company that develops personalized birth control methods. It provides medically actionable scientific insights and empowers individuals to proactively optimize their health—from birth control to fertility and beyond. The company's first product, the Birth Control Optimization Test, is an at-home kit enabling users to collect both saliva and finger prick samples to measure hormone baseline levels and aims to assess genetic risk for blood clots and depression. Adyn's technology then synthesizes a medical biography with side effect profiles of estrogens and progestins used in hormonal contraception. Elizabeth Ruzzo headquartered the company in Seattle, Washington in 2019 and is backed by Lux Capital, M13, Civilization Ventures, Concrete Rose Capital, Y Combinator, Madrona Pioneer Fund, and Ascend VC.
Alternative investments have become a growing staple in investor portfolios as investors continue to seek better portfolio diversification and higher returns. However investing in and alongside the most promising venture funds is primarily limited to institutional investors and industry insiders. We are here to change that.
Capsule is rebuilding the $425 billion pharmacy industry from the inside out with an emotionally resonant experience, and technology that enables customized outcomes for doctors, hospitals, insurers, and manufacturers. Our team makes the same promise to each other as the one we’ve made to our customers, doctors, and partners: everybody needs some looking after sometimes. We’ll never lose sight of the fact that behind all the craziness of the healthcare system, we’re just people looking after other people. Capsule has raised $70 million from Thrive Capital, Glade Brook Capital, and The Virgin Group.
Carenostics develops healthcare AI solutions to identify opportunities for earlier clinical intervention with chronic disease patients. We learn machine learning models from patient data collected in routine care, and integrate directly into provider EHRs to help physicians identify patients with undiagnosed chronic disease, project their decline over time, and match them to guideline / evidence-based treatment. Carenostics partners with leading providers, payers, pharma companies, care management companies, academics, and government agencies to address the gaps in chronic disease care. Our flagship solution, CKDx, is a clinical decision support tool developed with the goal of eradicating undiagnosed chronic kidney disease while reducing the disparities in care faced by minority populations.